Metabolomics of Right Ventricular Systolic Function Across the Spectrum of Pulmonary Hypertension – insights from the PVDOMICS Cohort
Abstract Body (Do not enter title and authors here): Introduction: PH increases RV afterload, often leading to RV systolic and diastolic failure. The metabolic mechanisms underlying RV dysfunction remain poorly understood and are largely unexplored across non-PAH forms of PH. Aims: We aimed to identify which metabolites and metabolic pathways associated with imaging measures of RV systolic function. Methods: We analyzed data from the multi-center PVDOMICS cohort, which includes echo, CMR, invasive hemodynamics, clinical phenotyping, and untargeted plasma metabolomics (via Metabolon). RV systolic function metrics selected as the outcome measures for this study were fractional area change (echo), global longitudinal strain (echo), and RVEF (CMR). Associations between non-xenobiotic, named metabolites and RV function measures were assessed using linear regression adjusted for age, sex, BMI, and PH group, with significance defined by FDR <0.05. Metabolite set enrichment analysis (MSEA) was performed to identify significantly enriched pathways (FDR <0.20). To complement MSEA, we conducted mean-aggregation analysis: we averaged metabolite concentrations within each pathway and tested associations with RV function using the same covariate adjustments (FDR <0.05). Results: We identified 979 participants with plasma metabolomics and at least one available outcome measure (317 Group 1 PH; 106 Group 2 PH; 140 Group 3 PH; 51 Group 4 PH; 26 Group 5 PH; 81 Healthy Controls; 258 Disease Comparators). Linear regression identified 170 metabolites from the 647 named metabolites significantly associated with all 3 RV metrics (Top 10 by average ranked p-value displayed in Image 1). MSEA revealed seven enriched pathways across all RV metrics: Androgenic Steroids, Pregnenolone Steroids, Progestin Steroids, Fatty Acid Metabolism (Acyl Choline), Histidine metabolism, Vitamin A metabolism, Gamma-glutamyl Amino Acid (Image 2). Mean aggregation analysis showed that higher concentrations of Androgenic/Pregnenolone Steroids and Vitamin A metabolites strongly associated with improved RV function, while higher levels of Fatty Acid Metabolism (Acyl Carnitine) and Acetylated Peptides associated with worse function (Image 3). Conclusions: Using data from the multi-institutional PVDOMICS cohort, we provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Steroid hormones as well as Vitamin A and fatty acid metabolites emerged as central to RV systolic function.
Garry, Jonah
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Racanelli, Alexandra
( NYP-Weill Cornell
, New York City
, New York
, United States
)
Brittain, Evan
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Hemnes, Anna
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Horn, Evelyn
( NYP-Weill Cornell
, New York City
, New York
, United States
)
Chung, Samuel
( NYP-Weill Cornell
, New York City
, New York
, United States
)
Chacon-barahona, Jonathan
( NYP-Weill Cornell
, New York City
, New York
, United States
)
Frantz, Robert
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Rischard, Franz
( The University of Arizona
, Tucson
, Arizona
, United States
)
Simpson, Catherine
( Johns Hopkins University
, Baltimore
, Maryland
, United States
)
Hassoun, Paul
( Johns Hopkins University
, Baltimore
, Maryland
, United States
)
Mathai, Stephen
( Johns Hopkins University
, Baltimore
, Maryland
, United States
)
Krumsiek, Jan
( NYP-Weill Cornell
, New York City
, New York
, United States
)
Author Disclosures:
Jonah Garry:DO NOT have relevant financial relationships
| Alexandra Racanelli:DO NOT have relevant financial relationships
| Evan Brittain:DO NOT have relevant financial relationships
| Anna Hemnes:DO have relevant financial relationships
;
Consultant:gossamerbio:Active (exists now)
; Consultant:Johnson and Johnson:Past (completed)
; Individual Stocks/Stock Options:Tenax Therapeutics:Active (exists now)
; Consultant:united therapeutics:Past (completed)
; Consultant:merck:Active (exists now)
| Evelyn Horn:DO have relevant financial relationships
;
Consultant:johnson and Johnson:Active (exists now)
; Researcher:aria CV:Active (exists now)
; Consultant:pulmovomed:Active (exists now)
; Consultant:trisol:Active (exists now)
; Consultant:Biotronik:Active (exists now)
; Consultant:SoniVie:Active (exists now)
| Samuel Chung:DO NOT have relevant financial relationships
| Jonathan Chacon-Barahona:DO NOT have relevant financial relationships
| Robert Frantz:No Answer
| Franz Rischard:DO have relevant financial relationships
;
Researcher:United Therapeutics:Active (exists now)
; Researcher:NIH/NHLBI:Active (exists now)
; Researcher:Insmed:Past (completed)
; Researcher:Merck:Active (exists now)
; Researcher:Orph AI:Active (exists now)
; Researcher:Bayer:Active (exists now)
| Catherine Simpson:DO NOT have relevant financial relationships
| Paul Hassoun:DO have relevant financial relationships
;
Advisor:Merck and Company, Inc.:Past (completed)
; Consultant:UT:Past (completed)
| Stephen Mathai:DO have relevant financial relationships
;
Advisor:Merck:Past (completed)
; Advisor:Gossamer:Past (completed)
; Advisor:United Therapeutics:Past (completed)
| Jan Krumsiek:DO NOT have relevant financial relationships